A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Joo-Heung | - |
dc.contributor.author | Youn, Jai-Il | - |
dc.contributor.author | Kim, Tae-Yoon | - |
dc.contributor.author | Choi, Jee-Ho | - |
dc.contributor.author | Park, Chul-Jong | - |
dc.contributor.author | Choe, Yong-Beom | - |
dc.contributor.author | Song, Hae-Jun | - |
dc.contributor.author | Kim, Nack-In | - |
dc.contributor.author | Kim, Kwang-Joong | - |
dc.contributor.author | Lee, Jeung-Hoon | - |
dc.contributor.author | Yoo, Hyun-Jeong | - |
dc.date.accessioned | 2021-09-03T21:51:07Z | - |
dc.date.available | 2021-09-03T21:51:07Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-07-25 | - |
dc.identifier.issn | 1471-5945 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88038 | - |
dc.description.abstract | Background: Etanercept, a soluble tumor necrosis factor receptor, and acitretin have been shown to be effective in treating psoriasis. Acitretin is widely used in Korea. However, the combination of etanercept plus acitretin has not been evaluated among Korean patients with psoriasis. The objective of this study was to investigate the efficacy and safety of combination therapy with etanercept and acitretin in patients with moderate to severe plaque psoriasis. Methods: Sixty patients with psoriasis were randomized to receive etanercept 50 mg twice weekly (BIW) for 12 weeks followed by etanercept 25 mg BIW for 12 weeks (ETN-ETN); etanercept 25 mg BIW plus acitretin 10 mg twice daily (BID) for 24 weeks (ETN-ACT); or acitretin 10 mg BID for 24 weeks (ACT). The primary efficacy measurement was the proportion of patients achieving 75 % improvement in Psoriasis Area and Severity Index (PASI 75) at week 24. Secondary end points included 50 % improvement in PASI (PASI 50) at week 24 and clear/almost-clear by Physician Global Assessment (PGA) at each visit through week 24. Results: The proportions of patients achieving PASI 75, PASI 50, and PGA clear/almost-clear at week 24 in the ETN-ETN (52.4, 71.4, and 52.4 %, respectively) and ETN-ACT groups (57.9, 84.2, and 52.6 %, respectively) were higher than in the ACT group (22.2, 44.4, and 16.7 %, respectively). The incidence of adverse events was similar across all arms. This was an open-label study with a small number of patients. Conclusion: In Korean patients with moderate to severe plaque psoriasis, etanercept alone or in combination with acitretin was more effective than acitretin. All treatments were well tolerated throughout the study. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.subject | PLAQUE PSORIASIS | - |
dc.subject | GUIDELINES | - |
dc.subject | MANAGEMENT | - |
dc.subject | ARTHRITIS | - |
dc.subject | CARE | - |
dc.subject | RETINOIDS | - |
dc.subject | RISK | - |
dc.title | A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Hae-Jun | - |
dc.identifier.doi | 10.1186/s12895-016-0048-z | - |
dc.identifier.scopusid | 2-s2.0-84979210369 | - |
dc.identifier.wosid | 000381029700001 | - |
dc.identifier.bibliographicCitation | BMC DERMATOLOGY, v.16 | - |
dc.relation.isPartOf | BMC DERMATOLOGY | - |
dc.citation.title | BMC DERMATOLOGY | - |
dc.citation.volume | 16 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordPlus | PLAQUE PSORIASIS | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | ARTHRITIS | - |
dc.subject.keywordPlus | CARE | - |
dc.subject.keywordPlus | RETINOIDS | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | Psoriasis | - |
dc.subject.keywordAuthor | Etanercept | - |
dc.subject.keywordAuthor | Acitretin | - |
dc.subject.keywordAuthor | Combination therapy | - |
dc.subject.keywordAuthor | Efficacy | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Korean patients | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.